Navigation Links
Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Date:9/30/2013

sks, uncertainties and assumptions that could cause actual results to differ materially from those described.  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 30, 2013, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. T
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
2. Amgen And Servier Complete Product Collaboration Transaction
3. Amgen Announces 2013 Third Quarter Dividend
4. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
5. Amgen And Servier Announce Product Collaboration
6. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
7. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
8. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
9. Amgen Announces 2013 Second Quarter Dividend
10. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
11. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Mount Dora, Florida (PRWEB) April 23, 2015 ... announced that it intends to conduct a groundbreaking ... can begin to be reversed in as little ... researchers—using the science of metabolic and nutritional medicine—will ... conditions that cripple and destroy our aging brain. ...
(Date:4/23/2015)... April 23, 2015 WuXi PharmaTech (Cayman) Inc. ... and technology platform company serving the pharmaceutical, biotechnology and ... and the United States ... for the first quarter of 2015 after the New ... (which will be Thursday morning, May 14, 2015 Shanghai ...
(Date:4/23/2015)... April 23, 2015 Glemser ... the first EMC® Enterprise Content Division (ECD) Certified ... EMC Documentum® for Life Sciences Solution Suite ... knowledge and capabilities to provide life sciences companies ... , The EMC Documentum Solution Suite offers ...
(Date:4/23/2015)... 23, 2015 ReliantHeart's HeartAssist5® Ventricular Assist ... flow through the device) in real time, and this ... world’s leading provider of Machine to Machine (M2M) communications ... Flow via VADLink.com can be monitored by ... drop in flow below a minimum threshold, the patient ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... TOKYO, Japan, October 14 ... a biopharmaceutical company,today announces the assignment of the ... Limited, a UK biotechnology company and subsidiary of,PepTcell ... a well-known,drug, were shown by Sosei to have ...
... , SAN DIEGO, Oct. 13 SpectraScience, Inc. (OTC ... company, today announced that it has engaged Bielderman BVBA, ... clinical process for its Barrett,s esophageal cancer application under ... be used in the Company,s application to the Food ...
... (Nasdaq: CPHD ) today announced that it will report ... on Wednesday, October 28, 2009, after the close of the ... 2 p.m. Pacific Time on Wednesday, October 28, 2009, to ... visit Cepheid,s website at www.cepheid.com/investors at ...
Cached Biology Technology:Sosei Announces Deal With UK Biotech Company 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 3Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast 2
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... metabolic pathway for breaking down glucose that could lead to ... The new pathway is intended to replace the ... reactions that nearly all organisms use to convert sugars into ... the six carbon atoms found in glucose into two-carbon molecules ...
... process required for repairing DNA breakage, scientists at the Duke ... deal with the barrage of damage that can contribute to ... week of Sept. 30, 2013, in the journal Proceedings ... work by the research team and identify new prospects for ...
... Davis Health System researchers have identified for the first ... sugar levels are abnormally high and causes irregular heartbeats, ... with heart failure and sudden cardiac death. ... the discovery helps explain why diabetes is a significant ...
Cached Biology News:UCLA engineers develop new metabolic pathway to more efficiently convert sugars into biofuels 2New insights into DNA repair process may spur better cancer therapies 2UC Davis researchers discover a biological link between diabetes and heart disease 2UC Davis researchers discover a biological link between diabetes and heart disease 3
Sf21 Insect Cells (Frozen) in Max-XP Medium...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... Ciphergen's ProteinChip arrays have been developed ... biological samples. A variety of ProteinChip ... proteins according to their unique biochemical ... spots, allowing side-by-side sample comparison, and ...
... Ciphergen's ProteinChip arrays have been developed ... biological samples. A variety of ProteinChip ... proteins according to their unique biochemical ... spots, allowing side-by-side sample comparison, and ...
Biology Products: